AOP-Wiki

API

All Key Events

Showing 1826 to 1850 of 1947 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

344	Increase, Liver fibrosis Short Name Increase, Liver fibrosis	1	Organ	Nov 29, 2016	Feb 11, 2026	11 AOPs 38: Protein Alkylation leading to Liver Fibrosis 144: Endocytic lysosomal uptake leading to liver fibrosis 383: Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis 494: AhR activation leading to liver fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis
1271	Increase, Transforming growth factor-beta signaling Short Name Activation of TGF-β signaling	0	Molecular	Feb 15, 2017	Feb 11, 2026	8 AOPs 206: Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 655: Activation of Transient Receptor Potential A1 (TRPA1) Leading to Pulmonary Fibrosis
459	Increase, Liver steatosis Short Name Increase, Liver steatosis	1	Organ	Nov 29, 2016	Feb 11, 2026	22 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis 62: AKT2 activation leading to hepatic steatosis 36: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) 285: Inhibition of N-linked glycosylation leads to liver injury 318: Glucocorticoid Receptor activation leading to hepatic steatosis 517: Pregnane X Receptor (PXR) activation leads to liver steatosis 518: Liver X Receptor (LXR) activation leads to liver steatosis 529: Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis 232: NFE2/Nrf2 repression to steatosis 57: AhR activation leading to hepatic steatosis 494: AhR activation leading to liver fibrosis 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 653: Inhibition to Microsomal Triglyceride Transfer Protein Leads to Steatosis
2119	Increase, Insulin resistance Short Name Increase, Insulin resistance	1	Organ	Apr 3, 2023	Feb 11, 2026	7 AOPs 457: Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine 454: PM2.5-related AOP frameworks on liver diseases 493: ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
1815	Increase, Endoplasmic reticulum stress Short Name Increase, ER stress	0	Cellular	Nov 2, 2020	Feb 11, 2026	5 AOPs 362: Immune mediated hepatitis 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 647: ROS formation leading to growth inhibition modulated by the Keap1–Nrf2 antioxidant response
115	Increase, Fatty acid influx Short Name Increase, FA influx	1	Cellular	Nov 29, 2016	Feb 11, 2026	2 AOPs 34: LXR activation leading to hepatic steatosis 517: Pregnane X Receptor (PXR) activation leads to liver steatosis
68	Increase, Collagen accumulation Short Name Increase, Collagen accumulation	1	Tissue	Nov 29, 2016	Feb 11, 2026	13 AOPs 38: Protein Alkylation leading to Liver Fibrosis 241: Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis 144: Endocytic lysosomal uptake leading to liver fibrosis 319: Binding to ACE2 leading to lung fibrosis 382: Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis 173: Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 494: AhR activation leading to liver fibrosis
1606	Activation, Stellate cell Short Name Activation, Stellate cell	0	Cellular	Mar 6, 2019	Feb 11, 2026	285: Inhibition of N-linked glycosylation leads to liver injury
265	Increase, Hepatic stellate cell activation Short Name Increase, HSC activation	1	Cellular	Nov 29, 2016	Feb 11, 2026	9 AOPs 38: Protein Alkylation leading to Liver Fibrosis 144: Endocytic lysosomal uptake leading to liver fibrosis 494: AhR activation leading to liver fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
177	Increase, Mitochondrial dysfunction Short Name Increase, Mitochondrial dysfunction	1	Cellular	Nov 29, 2016	Feb 11, 2026	43 AOPs 48: Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. 77: Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 78: Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 79: Nicotinic acetylcholine receptor activation contributes to impaired hive thermoregulation and leads to colony loss/failure 80: Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure 87: Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure 3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits 144: Endocytic lysosomal uptake leading to liver fibrosis 178: Nicotinic acetylcholine receptor activation contributes to mitochondrial dysfunction and leads to colony loss/failure 200: Estrogen receptor activation leading to breast cancer 273: Mitochondrial complex inhibition leading to liver injury 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 437: Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity 423: Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress 480: Mitochondrial complexes inhibition leading to heart failure via decreased ATP production 481: AOPs of amorphous silica nanoparticles: ROS-mediated oxidative stress increased respiratory dysfunction and diseases. 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 256: Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity 258: Renal protein alkylation leading to kidney toxicity 464: Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis 205: AOP from chemical insult to cell death 335: AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment 362: Immune mediated hepatitis 130: Phospholipase A2 (LPLA2) inhibitors leading to hepatotoxicity 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome 34: LXR activation leading to hepatic steatosis 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways 207: NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans 476: Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity 530: Endocytotic lysosomal uptake leads to intestinal barrier disruption 587: Inhibition of the mitochondrial complex III of nigro-striatal neurons leads to parkinsonian motor deficits 588: Inhibition of the mitochondrial complex II of nigro-striatal neurons leads to parkinsonian motor deficits 589: Inhibition of the mitochondrial complex IV of nigro-striatal neurons leads to parkinsonian motor deficits 595: Emerging OPFRS reproductive outcome pathway 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 636: Increase in reactive oxygen species (ROS) leading to human amyotrophic lateral sclerosis (ALS) 472: DNA adduct formation leading to kidney failure 645: Binding and activation of AhR lead to cardiovascular aging
2407	Increase, Cirrhosis Short Name Increase, Cirrhosis	0	Organ	Feb 10, 2026	Feb 11, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
122	Increase, Glucocorticoid receptor activation Short Name Increase, GR activation	1	Molecular	Nov 29, 2016	Feb 12, 2026	11 AOPs 14: Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility 214: Network of SSRIs (selective serotonin reuptake inhibitors) 318: Glucocorticoid Receptor activation leading to hepatic steatosis 334: Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration 581: Glucocorticoid receptor (GR) activation during development leads to cognitive function (COG) decrease 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
450	Decrease, Very low-density lipoprotein export capacity Short Name Decrease, VLDL export capacity	1	Cellular	Nov 29, 2016	Feb 12, 2026	57: AhR activation leading to hepatic steatosis
2410	Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Short Name Increase, 11β-HSD1 activity	0	Molecular	Feb 18, 2026	Feb 18, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2411	Increase, Circulating active glucocorticoid availability Short Name	0	Organ	Feb 18, 2026	Feb 24, 2026	None
465	Increased, Fatty acid influx Short Name Increased, FA Influx	1	Cellular	Nov 29, 2016	Feb 24, 2026	6 AOPs 57: AhR activation leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
1489	Increase, Steatohepatitis Short Name Increase, Steatohepatitis	0	Organ	Nov 13, 2017	Feb 24, 2026	9 AOPs 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) 401: G protein-coupled estrogen receptor 1 (GPER) signal pathway in the lipid metabolism disrupting effects 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2326	CTL cytotoxic activity disruption Short Name CTL cytotoxicity	1	Cellular	May 22, 2025	Feb 24, 2026	578: AhR activation leading to cancer progression via immunosuppression
2412	Increase, Hepatic intracellular active glucocorticoids Short Name	0	Cellular	Feb 18, 2026	Feb 26, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2409	Decrease, 11β-Hydroxysteroid dehydrogenase type 2 activity Short Name Decrease, 11β-HSD2 activity	0	Molecular	Feb 10, 2026	Feb 26, 2026	630: Decreased 11β-Hydroxysteroid dehydrogenase type 2 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction
2404	Increase, kidney fibrosis Short Name Increase, kidney fibrosis	0	Tissue	Feb 6, 2026	Feb 27, 2026	622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure
2413	Increased, uterine weight Short Name Increased, uterine weight	1	Organ	Mar 13, 2026	Mar 13, 2026	637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining
2082	Hypospadias, increased Short Name Hypospadias	1	Organ	Dec 18, 2022	Mar 20, 2026	4 AOPs 477: Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring 527: Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) leads to Hypospadias, increased 570: Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring 571: 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring
26	Antagonism, Androgen receptor Short Name Antagonism, Androgen receptor	1	Molecular	Nov 29, 2016	Mar 20, 2026	9 AOPs 306: Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring 344: Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring 345: Androgen receptor (AR) antagonism leading to decreased fertility in females 372: Androgen receptor antagonism leading to testicular cancer 477: Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring 476: Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity 19: Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) 595: Emerging OPFRS reproductive outcome pathway 619: Androgen receptor antagonism leads to delayed preputial separation via reduced fibroblast growth factor in genital-tubercle tissues
1617	Inhibition, 5α-reductase Short Name Inhibition, 5α-reductase	0	Molecular	Apr 18, 2019	Mar 20, 2026	5 AOPs 289: Inhibition of 5α-reductase leading to decreased population growth rate via impaired fecundity in female fish 305: 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring 120: Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) 571: 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring 576: 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring